Skip to content
10-Q

Quarterly Report

Protara Therapeutics, Inc. TARA

0001213900-26-055463

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 56.2M sh
Shares Diluted Q1 2026 · Mar 31, 2026 57.54M sh
Shares Diluted Q1 2026 · Mar 31, 2025 40.71M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$21.34M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$14.71M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $14.74M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $49.66M
Stockholders Equity Q1 2026 · Mar 31, 2026 $181.21M
Stockholders Equity Q1 2026 · Dec 31, 2025 $196.41M
Stockholders Equity Q1 2026 · Mar 31, 2025 $158.48M
Stockholders Equity Q1 2026 · Dec 31, 2024 $167.13M
Current Liabilities Q1 2026 · Mar 31, 2026 $8.92M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.94M
Total Liabilities Q1 2026 · Mar 31, 2026 $10.72M
Total Liabilities Q1 2026 · Dec 31, 2025 $13.06M
Current Assets Q1 2026 · Mar 31, 2026 $140M
Current Assets Q1 2026 · Dec 31, 2025 $159.5M
Total Assets Q1 2026 · Mar 31, 2026 $191.92M
Total Assets Q1 2026 · Dec 31, 2025 $209.47M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.31
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.29
Eps Basic Q1 2026 · Mar 31, 2026 −$0.31
Eps Basic Q1 2026 · Mar 31, 2025 −$0.29
Sga Expense Q1 2026 · Mar 31, 2026 $6.07M
Sga Expense Q1 2026 · Mar 31, 2025 $4.98M
Rd Expense Q1 2026 · Mar 31, 2026 $13.56M
Rd Expense Q1 2026 · Mar 31, 2025 $9.15M
Net Income Q1 2026 · Mar 31, 2026 −$17.78M
Net Income Q1 2026 · Mar 31, 2025 −$11.91M
Operating Income Q1 2026 · Mar 31, 2026 −$19.63M
Operating Income Q1 2026 · Mar 31, 2025 −$14.12M
Capex Q1 2026 · Mar 31, 2025 $44K